who should not take glp-1 receptor agonists Nutritional Deficiencies with weekly (Ozempic & Mounjaro): What patients Need to Updated guidance for patients using

GLP-1RAs thus prevent the occurrence of retinal damage associated with oxidative-stress-induced activation of glial cells and collectively foster a healthy retinal microenvironment by virtue of preventing cellular overexertion [94, 100]

GLP-1 agonists also stimulate pancreatic beta cells to secrete insulin and tamp down glucagon secretion from the pancreatic alpha cells

In summary, an increasing number of clinical studies support that GLP-1 RAs can improve the clinical and pathological changes in PD, providing long-term benefits for patients cognitive and motor symptoms

Mild to moderate side effects are often observed in the early weeks (~first 6) of medication use and during dose escalation

Moreover, the key circuits and neurotransmitters should be explored, whereby the GABAergic system is a candidate that deserves attention, given that GLP-1R is located presynaptically on such nerve terminals (Rebosio et al., 2018)

This discrepancy in clinical recommendations underscores the critical need for comprehensive real-world evidence studies to elucidate the safety profile and adverse reaction patterns associated with combination therapy